CTLA4 and cancer: Higher TIDE prediction scores are linked with worse immunotherapy response and unfavorable survival outcomes under anti-programmed cell death 1 receptor (PD1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA4) therapies in pan-cancer (Jiang et al., 2018).